• Thumbnail for Janus kinase 3
    janus family of kinases. Other members of the Janus family include JAK1, JAK2 and TYK2. Janus kinases (JAKs) are relatively large kinases of approximately...
    41 KB (5,166 words) - 16:45, 28 January 2023
  • A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more...
    37 KB (3,296 words) - 02:08, 8 November 2024
  • the kinase activity of the first. The four JAK family members are: Janus kinase 1 (JAK1) Janus kinase 2 (JAK2) Janus kinase 3 (JAK3) Tyrosine kinase 2 (TYK2)...
    9 KB (974 words) - 14:46, 22 June 2024
  • Thumbnail for Janus kinase 3 inhibitor
    Janus kinase 3 inhibitors, also called JAK3 inhibitors, are a new class of immunomodulatory agents that inhibit Janus kinase 3. They are used for the treatment...
    17 KB (2,126 words) - 15:12, 16 June 2024
  • Thumbnail for Janus kinase 2
    Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling...
    28 KB (3,166 words) - 19:57, 8 August 2024
  • JAK3 (Janus kinase 3) deficiency is a dysfunction in cytokine receptor signalling and their production of cytokines. JAK3 is a tyrosine protein kinase, an...
    6 KB (666 words) - 10:56, 1 October 2024
  • Thumbnail for Janus kinase 1
    them to escape their tumor and metastasize to other parts of the body. Janus kinase 1 has been shown to interact with: ELP2, GNB2L1 IL6ST, Grb2, IL2RB, IRS1...
    21 KB (2,423 words) - 20:04, 16 October 2024
  • Thumbnail for Ritlecitinib
    Ritlecitinib (category Non-receptor tyrosine kinase inhibitors)
    alopecia areata (hair loss). Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase. The most common side effects include headache...
    12 KB (705 words) - 02:49, 12 October 2024
  • bank Janus kinase, a family of intracellular, nonreceptor tyrosine kinases including Janus kinase 1 (JAK1) Janus kinase 2 (JAK2) Janus kinase 3 (JAK3)...
    1 KB (165 words) - 21:34, 5 June 2024
  • Thumbnail for Deuruxolitinib
    Deuruxolitinib (category Janus kinase inhibitors)
    It is a Janus kinase inhibitor selective for JAK1 and JAK2. Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for...
    9 KB (457 words) - 05:12, 6 October 2024
  • Thumbnail for Decernotinib
    Decernotinib (category Protein kinase inhibitors)
    Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also...
    5 KB (265 words) - 04:56, 13 June 2024
  • Thumbnail for Interleukin 15
    cell surface. Upon binding IL-15β subunit activates Janus kinase 1 (Jak1) and γc subunit Janus kinase 3 (Jak3), which leads to phosphorylation and activation...
    39 KB (4,458 words) - 06:59, 3 June 2024
  • Thumbnail for T-cell surface glycoprotein CD3 zeta chain
    have been found for this gene. CD247 has been shown to interact with Janus kinase 3 and Protein unc-119 homolog. Cluster of differentiation ZAP70 GRCh38:...
    5 KB (615 words) - 20:53, 3 March 2023
  • Thumbnail for Tofacitinib
    Tofacitinib (category Non-receptor tyrosine kinase inhibitors)
    course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes...
    35 KB (3,270 words) - 15:33, 10 October 2024
  • Thumbnail for Severe combined immunodeficiency
    combined immunodeficiencies". J Gene Med. 3 (3): 201–206. doi:10.1002/1521-2254(200105/06)3:3<201::AID-JGM195>3.0.CO;2-Z. PMID 11437325. Buckley R (2003)...
    34 KB (3,270 words) - 01:33, 14 August 2024
  • Thumbnail for Povorcitinib
    Povorcitinib (category Janus kinase inhibitors)
    A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis...
    4 KB (235 words) - 03:03, 31 October 2024
  • Thumbnail for CHZ868
    CHZ868 (category Janus kinase inhibitors)
    CHZ868 is a drug which acts as a Janus kinase inhibitor selective for the JAK2 subtype. It was one of the first Janus kinase inhibitors developed, originally...
    4 KB (271 words) - 20:23, 22 June 2024
  • Isoantigen Isograft Isotype (immunology) Janus kinase 3 deficiency Junctional diversity Killer activation receptor Kinase tyrosine-based inhibitory motif Kinetic-segregation...
    13 KB (1,237 words) - 01:24, 15 January 2024
  • Thumbnail for Momelotinib
    Momelotinib (category Janus kinase inhibitors)
    anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth. The most common adverse reactions...
    11 KB (476 words) - 04:27, 7 September 2024
  • Thumbnail for Baricitinib
    Baricitinib (category Janus kinase inhibitors)
    arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. Baricitinib is approved for...
    43 KB (3,613 words) - 18:17, 17 November 2024
  • Thumbnail for JAKMIP3
    Janus kinase and microtubule interacting protein 3 is a protein that in humans is encoded by the JAKMIP3 gene. GRCh38: Ensembl release 89: ENSG00000188385...
    506 bytes (71 words) - 11:16, 17 October 2022
  • Thumbnail for Jaktinib
    Jaktinib (category Janus kinase inhibitors)
    Jaktinib is a janus kinase inhibitor under development for myelofibrosis. It is a deuterated-drug analog of momelotinib. Zhang, Yi; Zhou, Hu; Jiang, Zhongxing;...
    4 KB (194 words) - 21:31, 3 September 2024
  • Thumbnail for List of skin conditions
    (ICF syndrome) Isolated IgA deficiency Isolated primary IgM deficiency Janus kinase 3 deficiency Leukocyte adhesion molecule deficiency LIG4 syndrome Myeloperoxidase...
    198 KB (17,956 words) - 10:27, 2 November 2024
  • Thumbnail for Tyrosine kinase 2
    with Janus family kinases (JAKs) to affect intracellular signaling. Cytokines including interleukins, interferons and hemopoietins activate the Janus kinases...
    25 KB (2,850 words) - 23:00, 12 November 2023
  • Thumbnail for Upadacitinib
    Upadacitinib (category Non-receptor tyrosine kinase inhibitors)
    spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved...
    46 KB (4,534 words) - 15:25, 4 November 2024
  • Thumbnail for Protein kinase
    kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins. (See JAK-STAT pathway.) Some kinases have dual-specificity kinase activities...
    15 KB (1,635 words) - 23:25, 13 August 2024
  • Thumbnail for X-linked severe combined immunodeficiency
    alpha, beta, and gamma subunits, the common gamma subunit activates Janus Kinase 3 (JAK3), which leads to the phosphorylation of Signal Transducer and...
    36 KB (4,335 words) - 20:14, 12 July 2024
  • G-proteins Janus kinases MAP Kinase Non-receptor tyrosine kinase Olfactory receptor Peroxiredoxin Rab family Rap family Ras family Receptor tyrosine kinases Rho...
    3 KB (275 words) - 04:29, 5 August 2024
  • Thumbnail for Ivarmacitinib
    Ivarmacitinib (category Janus kinase inhibitors)
    Ivarmacitinib (SHR0302) is a small molecule drug and selective janus kinase 1 (JAK1) inhibitor. It is being developed for ulcerative colitis, eczema, alopecia...
    7 KB (459 words) - 11:46, 6 August 2024
  • Thumbnail for Gusacitinib
    Gusacitinib (category Non-receptor tyrosine kinase inhibitors)
    acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK). It is...
    3 KB (246 words) - 20:24, 22 June 2024